SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (783)3/15/2006 8:21:29 AM
From: nigel bates  Read Replies (1) of 1022
 
Would be interesting to get 'Fred's' take on this...

TeGenero has developed a unique approach to balance T cell activation and expansion by triggering co-stimulatory CD receptors with novel monoclonal antibodies (MAB) that convert “co-stimulatory” CD receptors into directly activating “stimulatory” CD receptors. This technology can be used to expand conventional T cells which are immunocompetent and have the potential to specifically activate immunosuppressive regulatory T cells.

TeGenero has identified a functionally novel class of proprietary “superagonistic” monoclonal antibodies (SuperMAB®) directed against the important immuno- regulatory T cell antigen CD28. CD28 is the most efficient CD receptor that co-stimulates T cells in combination with the TCR. Activation of the CD28 signaling pathway requires simultaneous triggering of the TCR by antigen and of CD28 by its physiological membrane-bound ligands. In vitro, this process can be mimicked by using a combination of MABs with specificity for the TCR and CD28. TeGenero´s novel CD28-SuperMAB®, bypasses the requirement for TCR signaling and activates T cells regardless of their TCR specificity. CD28-SuperMAB® therefore represents the first universal T cell growth factor applicable for therapeutic purpose in the intact organism.

Structural and functional considerations indicate that the principle of “superagonistic” stimulation of T cell CD receptors by specially developed monoclonal antibodies is not restricted to the CD28 molecule but can be transferred to other important immunomodulatory CD receptors. TeGenero therefore applies proprietary know how gained with the CD28-SuperMAB® to generate other T cell specific therapeutic antibody candidates.

TeGenero’s SuperMAB® platform revolutionizes current therapeutic approaches to the treatment of immuno-deficiencies and autoimmune-inflammatory diseases. They do not only place co-stimulatory cell surface receptor in the center of novel MAB-based drug development efforts, they also pave the way into identification of novel targets for other classes of immunotherapeutic drugs based on SuperMAB®-specific mode of action...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News